Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Roche Holding AG
  6. News
  7. Summary
    ROG   CH0012032048

ROCHE HOLDING AG

(ROG)
  Report
Delayed Swiss Exchange  -  11:30 2022-08-18 am EDT
319.95 CHF   +1.04%
03:03aJemincare Announces Exclusive License Agreement with Genentech to Develop and Commercialize Novel Oral Androgen Receptor Degrader
CI
08/17FDA accepts supplemental Biologics License Application for Roche's Polivy combination for people with previously untreated diffuse large B-cell lymphoma
AQ
08/17Sanofi trial failure halts work on breast cancer treatment amcenestrant
RE
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

ROCHE HOLDINGS AG : Berenberg sticks Neutral

05/27/2022 | 08:16am EDT
share with twitter
share with LinkedIn
share with facebook

In his latest research note, analyst Luisa Hector confirms his recommendation. The broker Berenberg is keeping its Neutral rating. The target price remains unchanged at CHF 365.


© MarketScreener with dpa-AFX Analyser 2022
All news about ROCHE HOLDING AG
03:03aJemincare Announces Exclusive License Agreement with Genentech to Develop and Commercia..
CI
08/17FDA accepts supplemental Biologics License Application for Roche's Polivy combination f..
AQ
08/17Sanofi trial failure halts work on breast cancer treatment amcenestrant
RE
08/16Genentech - FDA Accepts Supplemental Biologics License Application for Genentech's Poli..
AQ
08/16Swiss Drugmaker Roche Gets US FDA Review for Lymphoma Treatment
MT
08/16FDA Accepts Supplemental Biologics License Application for Genentech's Polivy Combinati..
BU
08/16FDA accepts supplemental Biologics License Application for Roche's Polivy combination f..
GL
08/16U.S. Food and Drug Administration Accepts Supplemental Biologics License Application by..
CI
08/15Novartis fails again to reuse anti-inflammatory drug to treat lung cancer
RE
08/15Roche Unveils New Diagnostic Test for COVID-19 Immune Response
MT
More news
Analyst Recommendations on ROCHE HOLDING AG
More recommendations
Financials
Sales 2022 64 249 M 67 424 M 67 424 M
Net income 2022 14 824 M 15 557 M 15 557 M
Net Debt 2022 10 272 M 10 779 M 10 779 M
P/E ratio 2022 17,2x
Yield 2022 3,02%
Capitalization 263 B 276 B 276 B
EV / Sales 2022 4,25x
EV / Sales 2023 4,13x
Nbr of Employees 100 920
Free-Float 89,0%
Chart ROCHE HOLDING AG
Duration : Period :
Roche Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROCHE HOLDING AG
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 319,95 CHF
Average target price 374,13 CHF
Spread / Average Target 16,9%
EPS Revisions
Managers and Directors
Severin Schwan Chief Executive Officer & Executive Director
Alan Hippe Chief Financial & Information Officer
Christoph Franz Chairman
Levi A. Garraway Chief Medical Officer
Pascale Schmidt Chief Compliance Officer
Sector and Competitors
1st jan.Capi. (M$)
ROCHE HOLDING AG-16.47%273 077
JOHNSON & JOHNSON-2.04%440 598
ELI LILLY AND COMPANY14.70%301 034
PFIZER, INC.-16.56%276 521
ABBVIE INC.4.46%250 080
NOVO NORDISK A/S5.17%239 447